Dr. Brian Roy Weston, MD

Dr. Weston practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Weston's NPI, 1316144405, was assigned on July 2, 2007. Dr. Weston graduated from Royal College of Surgeons Ireland in 1999. Dr. Weston's Texas license number on file is M7751.

Dr. Weston's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Weston's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Weston practices. Vendor and product names are available with a free account.

Gastroenterology is Dr. Weston's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Weston is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Weston's licenses on file in 6 states: Texas, Arizona, Florida, Pennsylvania, Washington and Louisiana.

Dmand AI lists acid reflux, colonoscopy, irritable bowel syndrome (IBS) and upper GI endoscopy among the conditions Dr. Weston treats.

CMS data shows 543 Medicare services from Dr. Weston across 11 procedure codes in 2024, for 284 Medicare patients. Medicare paid $59,718 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 284 Medicare patients who saw Dr. Weston in 2024. The largest group is 65 to 74, with 156 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 2.15, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Weston's median patient age at 73, with 42% women.

In 2024, Dr. Weston wrote 51 Medicare Part D claims for 36 patients. 100% of them were for generic drugs. CMS names the drug for 44 of them, across 2 drugs with 11 or more claims each, at $294 in total drug cost. In 2023, CMS named 31 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Weston for performance year 2024, reported as part of a group. Dr. Weston accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Weston as offering telehealth. CMS counts 527 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Weston, more than 99% of the clinicians it reports for that procedure.

Dmand AI links 107 papers to Dr. Weston, published from 2012 to 2024. 2017 was the busiest year, with 11. The most frequent topics are Esophageal Neoplasms, Adenocarcinoma and Chemoradiotherapy. Dr. Weston has published most often in Oncology. Dr. Weston's most frequent co-authors are Manoop S. Bhutani, MD, Wayne L. Hofstetter, MD and Jeffrey Lee, MD.

CMS Open Payments shows 73 general payments to Dr. Weston from 9 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 96% of the total. Boston Scientific Corporation paid the most, $1,795.

Dr. Weston graduated from Royal College of Surgeons Ireland in 1999.

Dr. Weston is in network with 5 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 4. Check the plan with the practice before a visit.